Skip to content

Clinical observation of Jianpi Bushen Xiezhuo fang decoction for the intermittent gout patients with Pixu Shizhu zhen

Clinical observation of Jianpi Bushen Xiezhuo fang decoction for the intermittent gout patients with Pixu Shizhu zhen

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005564
Enrollment
Unknown
Registered
2022-01-31
Start date
2022-01-24
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout

Interventions

2:Febuxostat Tablets
1:jianpibushenxiezhuofang
3:benzbromarone

Sponsors

Chongqing Hospital of Traditional Chinese Medicine,
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: A) Patients who have met the classification criteria of acute gout arthritis in the past and have been diagnosed as gout, but have no obvious joint symptoms, still high blood uric acid, no subcutaneous tophi and chronic kidney damage. Since the target value for lowering uric acid in patients with gout is 360umol/L can be included in the group. B) TCM syndrome type conforms to the diagnosis criteria of spleen deficiency and dampness resistance syndrome. C) Aged between 18 and 75. D) Did not take any western medicine for lowering uric acid 2 weeks before enrollment. E) Willing to use the program and sign informed consent for clinical observation.

Exclusion criteria

Exclusion criteria: A) Consistent with intermittent gout diagnosis, but blood uric acid =360umol/L. B) patients with serious cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine and digestive diseases, and mental diseases. C) patients with other diseases whose therapeutic drugs (such as losartan, aspirin enteric-coated tablets, anti-tuberculosis tablets, etc.) affect the blood uric acid level. D) those who are taking proprietary Chinese medicine or Traditional Chinese medicine with similar efficacy. E) Patients with acute or chronic infection, high fever, tuberculosis, acute suppurative, infectious or malignant tumor. F) pregnant or lactating women. G) Under 18 or over 75 years of age. H) Allergic constitution and drug allergy.

Design outcomes

Primary

MeasureTime frame
Uric acid;

Secondary

MeasureTime frame
Number of acute gout attacks;TCM syndrome index;

Countries

china

Contacts

Public Contactwangshasha
frencence@163.com15334520604

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026